Although DC vaccination targeting tumor peptides have demonstrated auspicious results in rGB patient treatment, Antonios et al.98 strongly suggested that anti-PD-1/PD-L1 therapy significantly augmented the adaptive immune response of tumor patients in response to vaccination. The gene discussed is CD274; the disease is neoplasm.